Press releases
- NovaBay Pharmaceuticals Plan of Compliance Accepted by the NYSE American
- NovaBay Pharmaceuticals Announces Approval of All Proposals at its 2024 Annual Meeting of Stockholders and Provides Other Corporate Updates
- NovaBay Pharmaceuticals Launches Avenova Product Bundles for Individualized Relief from Multifactorial Dry Eye Symptoms
- NovaBay Pharmaceuticals Reports First Quarter 2024 Financial Results
- NovaBay Pharmaceuticals Announces Record Ordered Product Sales of Avenova-Branded Products in April through Amazon
- NovaBay Pharmaceuticals to Hold 2024 First Quarter Conference Call on May 9, 2024
- NovaBay Pharmaceuticals Announces New and Enhanced Direct-to-Consumer Marketing to Efficiently Engage Customers and Drive Avenova Sales
- NovaBay Pharmaceuticals Receives a NYSE American Notice Regarding Stockholder Equity
- NovaBay Pharmaceuticals Reports Preliminary Eyecare and Wound Care Revenue Increased 13% for the First Quarter of 2024 on Lower Sales and Marketing Expenses
- NovaBay Pharmaceuticals Reports 2023 Fourth Quarter and Full Year Financial Results
More ▼
Key statistics
As of last trade NovaBay Pharmaceuticals Inc (B9P:DUS) traded at 0.0925, -95.70% above its 52-week low of 2.15, set on Apr 23, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.00 |
---|---|
High | 0.00 |
Low | 0.00 |
Bid | -- |
Offer | -- |
Previous close | 3.24 |
Average volume | 0.00 |
---|---|
Shares outstanding | 1.15m |
Free float | 1.15m |
P/E (TTM) | -- |
Market cap | 3.26m USD |
EPS (TTM) | -108.80 USD |
Data delayed at least 15 minutes, as of May 30 2024 18:32 BST.
More ▼